.jpg "BeiGene Ltd (NASDAQ: BGNE)")
In a report released today, Yaron Werber from Cowen & Co. maintained a Buy rating on BeiGene Ltd (BGNE), with a price target of $170. The company’s shares opened today at $118.28, close to its 52-week low of $105.19.
According to TipRanks.com, Werber is a 4-star analyst with an average return of 12.1% and a 59.8% success rate. Werber covers the Healthcare sector, focusing on stocks such as Ultragenyx Pharmaceutical, Inc., Rocket Pharmaceuticals Inc, and Unum Therapeutics Inc.
BeiGene Ltd has an analyst consensus of Strong Buy, with a price target consensus of $180.
See today’s analyst top recommended stocks >>
The company has a one-year high of $220.10 and a one-year low of $105.19. Currently, BeiGene Ltd has an average volume of 304.6K.
Based on the recent corporate insider activity of 47 insiders, corporate insider sentiment is positive on the stock. This means that over the past quarter there has been an increase of insiders buying their shares of BGNE in relation to earlier this year.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
BeiGene Ltd. is a commercial-stage biopharmaceutical company, which engages in the development and commercialization of innovative molecularly targeted and immuno-oncology drugs for the treatment of cancer. It focuses on Zanubrutinib (BGB-3111), Tislelizumab (BGB-A317), and Pamiparib (BGB-290).
